Evidence map›Paper›PMID 33219463›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2021

Prognostic value of SPECT myocardial perfusion entropy in high-risk type 2 diabetic patients.

Loïc Djaileb, Alexandre Seiller, Marjorie Canu, Nicolas De Leiris, Alix Martin, Julie Poujol, Alicia Fraguas-Rubio, Julien Leenhardt, Adrien Carabelli, Alex Calizzano and 8 more

Registry-linked trialAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02316054 (Long-term Additive Prognostic Value of Heterogeneity Myocardial Perfusion Imaging of SPECT Over Clinical and Ischemia in High-risk Diabetic Patients.), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02316054 completednot on this map

Long-term Additive Prognostic Value of Heterogeneity Myocardial Perfusion Imaging of SPECT Over Clinical and Ischemia in High-risk Diabetic Patients.

TypeobservationalSponsorUniversity Hospital, GrenobleRan2007 to 2015Enrolled170ConditionsType 2 DiabetesArmsMPHI
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Adding value to myocardial perfusion scintigraphy: A prediction tool to predict adverse cardiac outcomes and risk stratify.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Loïc DjailebNuclear Medicine Department, Grenoble-Alpes University Hospital, Grenoble, France. LDjaileb@chu-grenoble.fr.ORCID https://orcid.org/0000-0003-2784-6367
Alexandre SeillerRadiopharmaceutiques Biocliniques, UMR UGA-INSERM U1039, Grenoble, France.
Marjorie CanuRadiopharmaceutiques Biocliniques, UMR UGA-INSERM U1039, Grenoble, France.
Nicolas De LeirisNuclear Medicine Department, Grenoble-Alpes University Hospital, Grenoble, France.
Alix MartinCardiology Department, Clinique Mutualiste, Grenoble, France.
Julie PoujolRadiopharmaceutiques Biocliniques, UMR UGA-INSERM U1039, Grenoble, France.
Alicia Fraguas-RubioRadiopharmaceutiques Biocliniques, UMR UGA-INSERM U1039, Grenoble, France.
Julien LeenhardtNuclear Medicine Department, Grenoble-Alpes University Hospital, Grenoble, France.
Adrien CarabelliRadiopharmaceutiques Biocliniques, UMR UGA-INSERM U1039, Grenoble, France.
Alex CalizzanoNuclear Medicine Department, Grenoble-Alpes University Hospital, Grenoble, France.
Marie De FondaumièreRadiopharmaceutiques Biocliniques, UMR UGA-INSERM U1039, Grenoble, France.
Alexis BroisatRadiopharmaceutiques Biocliniques, UMR UGA-INSERM U1039, Grenoble, France.
Michel DesvignesGIPSA-lab, CNRS, UMR 5216, Grenoble, France.
Gérald VanzettoRadiopharmaceutiques Biocliniques, UMR UGA-INSERM U1039, Grenoble, France.
Catherine GhezziRadiopharmaceutiques Biocliniques, UMR UGA-INSERM U1039, Grenoble, France.
Daniel FagretNuclear Medicine Department, Grenoble-Alpes University Hospital, Grenoble, France.
Laurent M Riou *Radiopharmaceutiques Biocliniques, UMR UGA-INSERM U1039, Grenoble, France.
Gilles Barone-Rochette *Radiopharmaceutiques Biocliniques, UMR UGA-INSERM U1039, Grenoble, France.
Inserm · FRCentre National de la Recherche Scientifique · FRClinique Mutualiste Chirurgicale · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRisk stratification of patients with type 2 diabetes mellitus (T2D) remains suboptimal. We hypothesized that myocardial perfusion entropy (MPE) quantified from SPECT myocardial perfusion images may provide incremental prognostic value in T2D patients independently from myocardial ischemia.

methodsT2D patients with very high and high cardiovascular risk were prospectively included (n = 166, 65 ± 12 years). Stress perfusion defect was quantified by visual evaluation of SPECT MPI. SPECT MPI was also used for the quantification of rest and stress MPE. The primary end point was major adverse cardiac events (MACEs) defined as cardiac death, myocardial infarction (MI), and myocardial revascularization > 3 months after SPECT.

resultsForty-four MACEs were observed during a 4.6-year median follow-up. Significant differences in stress MPE were observed between patients with and without MACEs (4.19 ± 0.46 vs. 3.93 ± 0.40; P ≤ .01). By Kaplan-Meier analysis, the risk of MACEs was significantly higher in patients with higher stress MPE (log-rank P ≤ 01). Stress MPE and stress perfusion defect (SSS ≥ 4) were significantly associated with the risk of MACEs (hazard ratio 2.77 and 2.06, respectively, P < .05 for both) after adjustment for clinical and imaging risk predictors as identified from preliminary univariate analysis. MPE demonstrated incremental prognostic value over clinical risk factors, stress test EKG and SSS as evidenced by nested models showing improved Akaike information criterion (AIC), reclassification (global continuous net reclassification improvement [NRI]: 63), global integrated discrimination improvement (IDI: 6%), and discrimination (change in c-statistic: 0.66 vs 0.74).

conclusionsStress MPE provided independent and incremental prognostic information for the prediction of MACEs in diabetic patients. TRIAL REGISTRATION NUMBER: NCT02316054 (12/12/2014).

Indexed as

Coronary Artery DiseaseDiabetes Mellitus, Type 2Myocardial Perfusion ImagingEntropyExercise TestHumansPerfusionPrognosisRisk AssessmentRisk FactorsTomography, Emission-Computed, Single-PhotonDiabetesMyocardial perfusionPerfusion entropyPrognosisSPECT

Identifiers

PMID33219463
OpenAlexW3100433831

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.